Lonza reports restated 2020 financials for sales, EBIT, EBITDA and CORE EBITDA Lonza now provides 2020 financials in the redesigned business structure to reflect divisional performance Prior to the reporting […]
Autor: Firma Lonza Group Ltd.
Lonza Announces Results of the 2021 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
47,080,080 shareholders delegated their votes to the independent proxy, representing 63.22% of the share capital Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as […]
Lonza Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp (CH) and Portsmouth (US)
. Lonza will invest approximately CHF 850 million to build two new state-of-the-art mammalian facilities and respond to customer demand regarding capacity, life cycle management and speed to market A […]
Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp
Lonza will invest CHF 200 million to construct a new manufacturing complex The 2000 m2 complex will include a customer dedicated manufacturing line for antibody-drug conjugate payload molecules The investment […]
Lonza finalise la cession de deux sites à NextPharma
Finalisation de la vente des sites Lonza de Ploermel (FR) et d’Edimbourg (UK) Un processus de transfert de propriété sans heurts reste une priorité Citation de Gordon Bates, président et […]
Lonza Completes Divestment of Two Sites to NextPharma
Completion of sale of Lonza sites in Ploermel (FR) and Edinburgh (UK) A seamless ownership transfer process remains a priority Quote from Gordon Bates, President and Head of Small Molecules, […]
Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven
Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion Divestment will allow Lonza to refocus its business as a pure-play […]
Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business
Lonza delivers on guidance1 with CHF 4.5 billion sales, 12.0%2 sales growth, and CHF 1.4 billion CORE EBITDA, resulting in a 31.2% margin Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) […]
NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms
. Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms Centers of excellence […]
Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates
Two new bioconjugation suites to provide high throughput conjugation for the commercialization of antibody-drug conjugates (ADCs) in Lonza’s Ibex®Dedicate 1500m2 of active manufacturing space in addition to established quality control […]